Long‐Term Response to Avelumab Maintenance Therapy and Durable Remission After Cessation in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis: A Case Report
This case highlights avelumab's potential to induce a profound and durable antitumor immune response, suggesting the possibility of a "functional cure" in a subset of patients. This provides valuable data for guiding clinical decisions on the optimal duration of therapy.
Authors
- Toshitaka Shin (ORCID: https://orcid.org/0000-0001-7015-4281)
- Hiroyuki Fujinami (ORCID: https://orcid.org/0000-0001-6285-3576)
- Shinro Hata (ORCID: https://orcid.org/0000-0002-6294-9815)
- Tadasuke Ando (ORCID: https://orcid.org/0000-0003-1470-6517)
- Toru Inoue (ORCID: https://orcid.org/0000-0002-8290-0322)
Institutions
- Oita University (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1002/iju5.70117
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00